Vulvovaginitis in Emergency Medicine Medication
- Author: Mark J Leber, MD, MPH; Chief Editor: Pamela L Dyne, MD more...
Medication Summary
Treatment should be aimed at bacterial, parasitic, or fungal infection.
Antibiotics
Class Summary
Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the clinical setting.[25]
A 7-day oral course yields a 90% cure, and single oral dose therapy yields an 80% cure. Relapses are common requiring a longer duration of treatment.[26] Combinations of antibiotics have no benefit.[25, 26] If single oral dose therapy is ineffective, either administer a second oral dose in 48 hours or initiate weeklong therapy. Some patients prefer intravaginal medication.[10] Treatment of bacterial vaginosis before 20 weeks' gestation may decrease preterm delivery.[27] Only those women who are symptomatic from bacterial vaginosis should be screened.[10, 28, 5] Topical metronidazole gel poorly achieves therapeutic concentration in the urethra and Skene's gland and therefore is not indicated in Trichomonas infections.[19] Tinidazole may have less side effects than metronidazole and can be used in the rare case of metronidazole resistance.[29]
Metronidazole (Metro-Gel, Noritate)
Imidazole ring-based antibiotic active against various anaerobic bacteria and protozoa. Indicated for treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, anaerobic vaginosis).
Penicillin VK (Veetids, Beepen-VK)
Indicated when the offending organism is group A streptococci. Inhibits biosynthesis of cell wall mucopeptide and is effective during active replication. Inadequate concentrations may produce only bacteriostatic effects.
Tinidazole (Tindamax)
5-Nitroimidazole derivative used for susceptible protozoal infections. The mechanism by which tinidazole exhibits activity against Giardia and Entamoeba species is not known.
Erythromycin (EES, E-Mycin, Ery-Tab)
DOC for penicillin-allergic patients with infections caused by susceptible strains of microorganisms, including group A streptococci. Inhibits RNA-dependent protein synthesis, possibly by stimulating dissociation of peptidyl tRNA from ribosomes, which inhibits bacterial growth.
In children, age, weight, and severity of infection determine proper dosage. When bid dosing is desired, half-total daily dose may be taken q12h. For more severe infections, double the dose.
Clindamycin (C/T/S, Clinda-Derm, Cleocin HCl)
Useful as treatment against serious skin and soft tissue infections caused by most staphylococcal strains. Inhibits bacterial protein synthesis by inhibiting peptide chain initiation at the bacterial ribosome, where it preferentially binds to the 50S ribosomal subunit, causing bacterial growth inhibition. Has a 90% cure rate and is used as an alternative to metronidazole.
Corticosteroids
Class Summary
These agents are used to treat extreme vaginal pruritus. Cream is for symptomatic relief, especially in pediatric vulvovaginitis.
These agents are adrenocorticosteroid derivatives incorporated into a vehicle suitable for application to skin or external mucous membranes.
Hydrocortisone topical (Cortef Feminine Itch, Delcort)
DOC because of its mineralocorticoid activity and glucocorticoid effects.
Primary therapeutic effects of topical corticosteroids are from their anti-inflammatory activity, which is nonspecific (ie, they act against most causes of inflammation including mechanical, chemical, microbiological, immunological).
Do not use very high or high-potency agents on the face, groin, or axilla.
Antifungal agents
Class Summary
These agents are used to treat candidal vulvovaginitis. Topical azole antifungals achieve cure rates of 85-95%. Nystatin demonstrates a 75-80% cure rate. Oral fluconazole has a cure rate comparable to topical azole antifungals.[30] It may be preferred by patients because of the ease of one-time dosing.
Intravaginal and topical therapies with a variety of antifungals, such as clotrimazole, miconazole, terconazole, and tioconazole, are highly effective. Many of the preparations are now available OTC. 1-, 3-, and 7-day regimens can be used. Cure rates of 90% are reported with longer courses.
Butoconazole (Femstat)
Broad-spectrum antifungal agent that inhibit yeast growth by altering cell membrane permeability, which causes fungal cell death.
Tioconazole (Vagistat)
Broad-spectrum antifungal agent that inhibit yeast growth by altering cell membrane permeability, which causes fungal cell death.
Clotrimazole (Mycelex-7)
Broad-spectrum antifungal agents that inhibit yeast growth by altering cell membrane permeability, which causes fungal cell death.
Fluconazole (Diflucan)
Synthetic oral antifungal (broad-spectrum bistriazole) that selectively inhibits fungal cytochrome P-450 and sterol C-14 alpha-demethylation. Consider ease of use, although direct cost may be a limiting factor. Do not recommend PO antifungals in pregnancy.
Miconazole vaginal (Monistat Vaginal)
Broad-spectrum antifungal agent that inhibit yeast growth by altering cell membrane permeability, which causes fungal cell death.
Terconazole (Terazol 3, Terazol 7)
Broad-spectrum antifungal agent that inhibit yeast growth by altering cell membrane permeability, which causes fungal cell death.
Ketoconazole topical (Kuric 2%, Xolegel 2%)
Broad-spectrum antifungal agents that inhibit yeast growth by altering cell membrane permeability, which causes fungal cell death.
Nystatin
Broad-spectrum antifungal agent that inhibit yeast growth by altering cell membrane permeability, which causes fungal cell death.
Estrogens
Class Summary
These agents are used in treatment of atrophic vaginitis in postmenopausal women. Oral estrogen replacement also is effective and has other health benefits. Oral estrogen therapy generally should be initiated by a primary care provider rather than an ED clinician.
Conjugated estrogens (Premarin)
Several topical steroid preparations are available, including equine estrogen, estradiol, and dienestrol. Estrogens are indicated for atrophic vaginitis and atrophic urethritis associated with menopause.
Anthelmintics
Class Summary
These agents are used to treat parasitic infections. Parasite biochemical pathways are sufficiently different from the human host to allow selective interference by chemotherapeutic agents in relatively small doses.
Mebendazole (Vermox)
Indicated drug to treat pinworm. Kills worms by selectively and irreversibly blocking glucose uptake and other nutrients in the susceptible adult intestine where helminths dwell.
Pyrantel pamoate (Pin-Rid, Pin-X, Reese Pinworm)
Used as an alternative to mebendazole; a depolarizing neuromuscular blocking agent that inhibits cholinesterases, resulting in spastic paralysis of the worm. Active against E vermicularis (ie, pinworm) and Ascaris lumbricoides (ie, roundworm). Also effective against Ancylostoma duodenale (ie, hookworm). Purging is not necessary; may be taken with milk or fruit juices.
Estrogen receptor antagonists
Class Summary
These agents competitively bind to estrogen receptor, producing a nuclear complex that decreases DNA synthesis and inhibits estrogen effects.
Tamoxifen (Nolvadex)
May be used for women who are very concerned about estrogen exposure. Known to have both estrogen antagonist and agonist effects, depending on target tissue.
B Angotti L, C Lambert L, E Soper D. Vaginitis: making sense of over-the-counter treatment options. Infect Dis Obstet Gynecol. 2007;2007:97424. [Medline].
Nyirjesy P. Vulvovaginal candidiasis and bacterial vaginosis. Infect Dis Clin North Am. Dec 2008;22(4):637-52, vi. [Medline].
Katz. Vaginitis. In: Mosby. Katz:Comprehensive Gynecology. 5th ed. Elsevier; 2007:588-596.
Szumigala JA, Alveredo R. Vulvovaginitis. In: Mosby. Ferri: Ferri's Clinical Advisor 2009. ed. Elsevier; 2009:155,1008-1012.
[Guideline] Workowski KA, Berman SM. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines 2006. 2009;[Full Text].
Eckert LO. Clinical practice. Acute vulvovaginitis. N Engl J Med. Sep 21 2006;355(12):1244-52. [Medline].
Margesson LJ. Vulvar disease pearls. Dermatol Clin. Apr 2006;24(2):145-55, v. [Medline].
Braverman Paula k. Urethritis, Vulvovaginitis, and Cervicitis. In: Churchill Livingstone. Principals and Practice of Pediatric Infectious Diseases. 3rd ed. Elsevier; 2008:55.
Farage MA, Miller KW, Ledger WJ. Determining the cause of vulvovaginal symptoms. Obstet Gynecol Surv. Jul 2008;63(7):445-64. [Medline].
Biggs WS, Williams RM. Common gynecologic infections. Prim Care. Mar 2009;36(1):33-51, viii. [Medline].
Hampton T. High prevalence of lesser-known STDs. JAMA. Jun 7 2006;295(21):2467. [Medline].
Helms DJ, Mosure DJ, Metcalf CA, Douglas JM Jr, Malotte CK, Paul SM, et al. Risk factors for prevalent and incident Trichomonas vaginalis among women attending three sexually transmitted disease clinics. Sex Transm Dis. May 2008;35(5):484-8. [Medline].
Jasper J. Vulvovaginitis in the prepubertal child. Clin Pediatr Emerg Med. Mar 2009;10.
Freeto JP, Jay MS. "What's really going on down there?" A practical approach to the adolescent who has gynecologic complaints. Pediatr Clin North Am. Jun 2006;53(3):529-45, viii. [Medline].
Johnson E, Berwald N. Evidence-based emergency medicine/rational clinical examination abstract. Diagnostic utility of physical examination, history, and laboratory evaluation in emergency department patients with vaginal complaints. Ann Emerg Med. Sep 2008;52(3):294-7. [Medline].
Ferris DG, Francis SL, Dickman ED, Miler-Miles K, Waller JL, McClendon N. Variability of vaginal pH determination by patients and clinicians. J Am Board Fam Med. Jul-Aug 2006;19(4):368-73. [Medline].
Kulp JL, Chaudhry S, Wiita B, Bachmann G. The accuracy of women performing vaginal pH self-testing. J Womens Health (Larchmt). May 2008;17(4):523-6. [Medline].
Chatwani AJ, Mehta R, Hassan S, Rahimi S, Jeronis S, Dandolu V. Rapid testing for vaginal yeast detection: a prospective study. Am J Obstet Gynecol. Apr 2007;196(4):309.e1-4. [Medline].
Hollier LM, Workowski K. Treatment of sexually transmitted infections in women. Infect Dis Clin North Am. Dec 2008;22(4):665-91, vi. [Medline].
Pillay A, Radebe F, Fehler G, Htun Y, Ballard RC. Comparison of a TaqMan-based real-time polymerase chain reaction with conventional tests for the detection of Trichomonas vaginalis. Sex Transm Infect. Apr 2007;83(2):126-9. [Medline].
Schwiertz A, Taras D, Rusch K, Rusch V. Throwing the dice for the diagnosis of vaginal complaints?. Ann Clin Microbiol Antimicrob. Feb 17 2006;5:4. [Medline].
Heller DS, Maslyak S, Skurnick J. Is the presence of Trichomonas on a Pap smear associated with an increased incidence of bacterial vaginosis?. J Low Genit Tract Dis. Jul 2006;10(3):137-9. [Medline].
[Guideline] Huntzinger A. Practice Guideline Briefs. American Family Physician. Nov 2006;74.
Mania-Pramanik J, Kerkar SC, Mehta PB, Potdar S, Salvi VS. Use of vaginal pH in diagnosis of infections and its association with reproductive manifestations. J Clin Lab Anal. 2008;22(5):375-9. [Medline].
Schwebke JR, Desmond R. A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J Obstet Gynecol. Jun 2007;196(6):517.e1-6. [Medline].
Schwebke JR, Desmond RA. A randomized trial of the duration of therapy with metronidazole plus or minus azithromycin for treatment of symptomatic bacterial vaginosis. Clin Infect Dis. Jan 15 2007;44(2):213-9. [Medline].
Swadpanich U, Lumbiganon P, Prasertcharoensook W, Laopaiboon M. Antenatal lower genital tract infection screening and treatment programs for preventing preterm delivery. Cochrane Database Syst Rev. Apr 16 2008;CD006178. [Medline].
Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. Feb 24 2000;342(8):534-40. [Medline].
Nailor MD, Sobel JD. Tinidazole for the treatment of vaginal infections. Expert Opin Investig Drugs. May 2007;16(5):743-51. [Medline].
Marrazzo J. Vulvovaginal candidiasis. BMJ. Sep 14 2002;325(7363):586. [Medline].
Mann JR, McDermott S, Zhou L, Barnes TL, Hardin J. Treatment of trichomoniasis in pregnancy and preterm birth: an observational study. J Womens Health (Larchmt). Apr 2009;18(4):493-7. [Medline].
[Best Evidence] Buckling J. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst. Rev. 2006;4:[Medline].
Donders G, Bellen G, Byttebier G, Verguts L, Hinoul P, Walckiers R, et al. Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol. Dec 2008;199(6):613.e1-9. [Medline].
Van Der Pol B, Kwok C, Pierre-Louis B, Rinaldi A, Salata RA, Chen PL, et al. Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. J Infect Dis. Feb 15 2008;197(4):548-54. [Medline].
Gabbe SG. Vaginal infections. In: Obstetrics - Normal and Problem Pregnancies. 4th ed. 2002.
Johns Hopkins. Diagnostic features and management of vaginal infections. In: The Harriet Lane Handbook: A Manual for Pediatric House Officers. 17th ed. 2005.
Owen MK, Clenney TL. Management of vaginitis. Am Fam Physician. Dec 1 2004;70(11):2125-32. [Medline].
Sobel JD. Vaginitis, vulvitis, cervicitis and cutaneous vulval lesions. In: Infectious Diseases. 2nd ed. Cohen & Powderly; 2004.

